Ann: HEPATITIS C TRIAL UPDATE, page-27

I can understand the patient by patient commentary being ongoing to be a bit of a pain. Having said that BLT had no other choice as they created expectations and ten had to explain delays. I can see why they don't want to keep on doing this.

BLT has however a continuous disclosure obligation. At a minimum there should: eg,
1. Results of Cohort 2 (in aggregate, not patient by patient).
2. The tick of the DSMB to continue.
3. A statement that all patients in Cohort 3 have been dosed when it occurs.
4. Results of Cohort 3.
5.6,, 7 etc...As for Cohorts 4 and 5.

Does BLT management think they can wait potentially until the end of Cohort 5, with the catchphrase "material" being the ultimate tool in flexibility of reporting?
This is a structured trial, which has been marketed as such, and BLT should be obligated to report against milestones along the lines of that structure.